These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20625122)

  • 21. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
    Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
    Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).
    Gupta V; Yi QL; Brandwein J; Lipton JH; Messner HA; Schuh AC; Wells RA; Minden MD
    Leuk Res; 2005 Jan; 29(1):113-4. PubMed ID: 15541484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).
    Chim CS; Kwong YL; Liang R; Chu YC; Chan CH; Chan LC; Wong KF; Chan TK
    Hematol Oncol; 1996 Sep; 14(3):147-54. PubMed ID: 9119359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients.
    Liu YJ; Wu DP; Liang JY; Qiu HY; Jin ZM; Tang XW; Fu CC; Ma X
    Med Oncol; 2011 Dec; 28 Suppl 1():S513-21. PubMed ID: 21069477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of additional chromosome abnormalities on the outcome of newly diagnosed acute promyelocytic leukemia treated with red arsenic sulfide and all trans-retinoic acid plus anthracyclin based protocol].
    Lu J; Jiang H; Jiang Q; Bao L; Lu XJ; Zhang Y; Lin W; Liu YR; Huang XJ; Jiang B
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(32):2254-7. PubMed ID: 19087672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.
    Bally C; Fadlallah J; Leverger G; Bertrand Y; Robert A; Baruchel A; Guerci A; Recher C; Raffoux E; Thomas X; Leblanc T; Idres N; Cassinat B; Vey N; Chomienne C; Dombret H; Sanz M; Fenaux P; Adès L
    J Clin Oncol; 2012 May; 30(14):1641-6. PubMed ID: 22473162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy.
    Martinelli G; Ottaviani E; Testoni N; Visani G; Diverio D; D'Elia G; Mandelli F; Tura S
    Haematologica; 1998 Nov; 83(11):985-8. PubMed ID: 9864917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
    Kelaidi C; Chevret S; De Botton S; Raffoux E; Guerci A; Thomas X; Pigneux A; Lamy T; Rigal-Huguet F; Meyer-Monard S; Chevallier P; Maloisel F; Deconinck E; Ferrant A; Fegueux N; Ifrah N; Sanz M; Dombret H; Fenaux P; Adès L
    J Clin Oncol; 2009 Jun; 27(16):2668-76. PubMed ID: 19414681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?
    Park JH; Tallman MS
    Expert Rev Hematol; 2011 Aug; 4(4):427-36. PubMed ID: 21801134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors.
    Latagliata R; Breccia M; Fazi P; Vignetti M; Di Raimondo F; Sborgia M; Vincelli D; Candoni A; Salvi F; Rupoli S; Martinelli G; Kropp MG; Tonso A; Venditti A; Melillo L; Cimino G; Petti MC; Avvisati G; Lo-Coco F; Mandelli F;
    Br J Haematol; 2011 Sep; 154(5):564-8. PubMed ID: 21751984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
    Kelaidi C; Ades L; Chevret S; Sanz M; Guerci A; Thomas X; de Botton S; Raffoux E; Rayon C; Fegueux N; Bordessoule D; Rigal-Huguet F; Link H; Stoppa A; Vekhoff A; Meyer-Monard S; Castaigne S; Dombret H; Degos L; Fenaux P
    Leukemia; 2006 May; 20(5):905-7. PubMed ID: 16541143
    [No Abstract]   [Full Text] [Related]  

  • 33. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.
    Sanz MA; Martín G; González M; León A; Rayón C; Rivas C; Colomer D; Amutio E; Capote FJ; Milone GA; De La Serna J; Román J; Barragán E; Bergua J; Escoda L; Parody R; Negri S; Calasanz MJ; Bolufer P;
    Blood; 2004 Feb; 103(4):1237-43. PubMed ID: 14576047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy.
    Serefhanoglu S; Buyukasik Y; Goker H; Sayinalp N; Haznedaroglu IC; Aksu S; Ozcebe OI; Turgut M; Aslan R; Ozdemir E
    Leuk Res; 2010 Dec; 34(12):e317-9. PubMed ID: 20696473
    [No Abstract]   [Full Text] [Related]  

  • 35. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience.
    Lobe I; Rigal-Huguet F; Vekhoff A; Desablens B; Bordessoule D; Mounier C; Ferrant A; Sanz M; Fey M; Chomienne C; Chevret S; Degos L; Fenaux P;
    Leukemia; 2003 Aug; 17(8):1600-4. PubMed ID: 12886249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution.
    Pollicardo N; O'Brien S; Estey EH; al-Bitar M; Pierce S; Keating M; Kantarjian HM
    Leukemia; 1996 Jan; 10(1):27-31. PubMed ID: 8558933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk-adapted treatment for low- and intermediate-risk acute promyelocytic leukemia.
    Sanz MA; Montesinos P
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10 Suppl 3():S130-4. PubMed ID: 21115431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol.
    Pellicori P; Calicchia A; Lococo F; Cimino G; Torromeo C
    Congest Heart Fail; 2012; 18(4):217-21. PubMed ID: 22809260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
    Montesinos P; Rayón C; Vellenga E; Brunet S; González J; González M; Holowiecka A; Esteve J; Bergua J; González JD; Rivas C; Tormo M; Rubio V; Bueno J; Manso F; Milone G; de la Serna J; Pérez I; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA; ;
    Blood; 2011 Feb; 117(6):1799-805. PubMed ID: 21148082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    de Botton S; Sanz MA; Chevret S; Dombret H; Martin G; Thomas X; Mediavilla JD; Recher C; Ades L; Quesnel B; Brault P; Fey M; Wandt H; Machover D; Guerci A; Maloisel F; Stoppa AM; Rayon C; Ribera JM; Chomienne C; Degos L; Fenaux P; ;
    Leukemia; 2006 Jan; 20(1):35-41. PubMed ID: 16307026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.